In this era of revolutionary insights into the basic scientific principles underlying human diseases, there is continuing concern that advances in biomedical sciences do not translate directly into advances in public health care. In the last decade, the clinical research environment has been challenged by multiple factors including lack of translational research in clinical trials, fragmented oversight of clinical research, funding limitations in the health care system, and a shortage of qualified investigators. Outstanding and comprehensive clinical research training of future clinical investigators with a foundation in basic sciences must be an essential component of this process. This application by Memorial Sloan- Kettering Cancer Center (MSKCC) for the Paul Calabresi Award for Clinical Oncology (K12) brings this institution one step closer to achieving this goal of providing comprehensive training in the design, conduct and ethics of state-of-the-art clinical research for highly motivated trainees (both MDs and PhDs) dedicated to academic careers. We believe this is possible because of two key developments. The first is the successful recompetition of the K30 program which forms a critical part of the clinical oncology training program at MSKCC. The second is the establishment of the Louis V. Gerstner, Jr. Graduate School of Biomedical Science which will allow the awarding of PhDs in Cancer Biology for the first time at MSKCC. This comprehensive research training environment at MSKCC now provides the opportunity to achieve the goals of the K12: the successful career development of both MDs and PhDs in clinical cancer medicine utilizing a firm foundation in laboratory research to reach out and establish clinical trials programs. Trainees eligible for this grant are defined as future investigators in patient-oriented research. The principal aim of the K12 is to provide comprehensive training in the design, conduct and ethics of state-of-the-art clinical research for highly motivated trainees dedicated to academic careers. This program will provide the trainee the ability to: 1. Perform clinical therapeutic research that develops and tests scientific hypotheses based on fundamental and clinical research findings; 2. Design and conduct hypothesis-based, clinical therapeutic protocols which prospectively evaluate both clinical and relevant biological endpoints; 3. Conduct cancer therapeutic research in a team setting in which basic and clinical scientists collaborate and interact to expedite the translation of basic research into patient-oriented therapeutic cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
5K12CA120121-05
Application #
7858207
Study Section
Special Emphasis Panel (ZCA1-RTRB-L (J1))
Program Officer
Lei, Ming
Project Start
2006-06-19
Project End
2012-05-31
Budget Start
2010-06-22
Budget End
2012-05-31
Support Year
5
Fiscal Year
2010
Total Cost
$663,678
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Pennicooke, Brenton; Laufer, Ilya; Sahgal, Arjun et al. (2016) Safety and Local Control of Radiation Therapy for Chordoma of the Spine and Sacrum: A Systematic Review. Spine (Phila Pa 1976) 41 Suppl 20:S186-S192
Schaer, David A; Budhu, Sadna; Liu, Cailian et al. (2013) GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. Cancer Immunol Res 1:320-31
Schaer, David A; Murphy, Judith T; Wolchok, Jedd D (2012) Modulation of GITR for cancer immunotherapy. Curr Opin Immunol 24:217-24
Schaer, David A; Lesokhin, Alexander M; Wolchok, Jedd D (2011) Hiding the road signs that lead to tumor immunity. J Exp Med 208:1937-40
Schaer, David A; Li, Yongbiao; Merghoub, Taha et al. (2011) Detection of intra-tumor self antigen recognition during melanoma tumor progression in mice using advanced multimode confocal/two photon microscope. PLoS One 6:e21214
Carvajal, Richard D; Antonescu, Cristina R; Wolchok, Jedd D et al. (2011) KIT as a therapeutic target in metastatic melanoma. JAMA 305:2327-34
Cohen, Adam D; Schaer, David A; Liu, Cailian et al. (2010) Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One 5:e10436
Serbina, Natalya V; Cherny, Mathew; Shi, Chao et al. (2009) Distinct responses of human monocyte subsets to Aspergillus fumigatus conidia. J Immunol 183:2678-87
Serbina, Natalya V; Hohl, Tobias M; Cherny, Mathew et al. (2009) Selective expansion of the monocytic lineage directed by bacterial infection. J Immunol 183:1900-10
Saenger, Yvonne M; Li, Yanyun; Chiou, Karoline C et al. (2008) Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma. Cancer Res 68:9884-91

Showing the most recent 10 out of 11 publications